Discovery Indigenous Researchers Development - Grant ID: DI0989521
Funder
Australian Research Council
Funding Amount
$150,000.00
Summary
A Qualitative Study of Barriers to Effective Infectious and Parasitic Disease Interventions in Aboriginal Communities. This project is significant and innovative as it will enhance current understandings of the experience Indigenous communities have with infectious diseases. To date there have been no significant qualitative studies that examine the perceptions Indigenous communities have about infectious disease treatment interventions that draw on their current knowledge, experiences and on he ....A Qualitative Study of Barriers to Effective Infectious and Parasitic Disease Interventions in Aboriginal Communities. This project is significant and innovative as it will enhance current understandings of the experience Indigenous communities have with infectious diseases. To date there have been no significant qualitative studies that examine the perceptions Indigenous communities have about infectious disease treatment interventions that draw on their current knowledge, experiences and on health, functionality and well-being. This study will develop a model that Indigenous communities, clinicians, policy makers and researchers can use to guide the implementation of sustainable infectious disease interventions. The outcomes of this project will help guide, inform and improve future infectious disease intervention strategies and programs.Read moreRead less
Development of an effective vaccine for chlamydial infection: optimisation of a non-toxic cholera toxin-based adjuvant to generate a protective mucosal response. Chlamydial genital infections are the most common sexually transmitted infection in Australia and the world and impose a major health burden on the community. Chlamydial infections are also associated with cardiovascular disease, Australia's biggest killer and asthma, another condition that has increased significantly in prevalence in t ....Development of an effective vaccine for chlamydial infection: optimisation of a non-toxic cholera toxin-based adjuvant to generate a protective mucosal response. Chlamydial genital infections are the most common sexually transmitted infection in Australia and the world and impose a major health burden on the community. Chlamydial infections are also associated with cardiovascular disease, Australia's biggest killer and asthma, another condition that has increased significantly in prevalence in the past 10 years. This project will evaluate the effectiveness of a new adjuvant as a first step towards the development of a vaccine to target these important infections.Read moreRead less
Australian Partnership (for) Preparedness Research On InfectiouS (disease) Emergencies (APPRISE)
Funder
National Health and Medical Research Council
Funding Amount
$4,996,416.00
Summary
We have assembled national experts in clinical, laboratory and public health research to ensure Australia is equipped for a coordinated, effective and evidence based response to infectious diseases. This multidisciplinary team will create and share new knowledge to detect, prevent and manage emerging infection threats. We will train a robust cross-sectoral work force and develop sustainable research capacity integrated within the health system to ensure national and regional health security.
Diseases caused by the pneumococcus represent the largest cause of vaccine preventable death in the world today, mainly pneumonia and meningitis. In 2011, 16 developing countries will introduce pneumococcal conjugate vaccines, none in east Asia. Lack of research has been a major barrier to their use in the region. We have established an international centre of excellence in the field and we seek support to extend the capacity of this group and to transfer the technology to Vietnam.
Identification of new antibacterial agents that inhibit type III secretion. The development of new antibacterial drugs is an unmet global health priority. This project will investigate several plant-derived compounds that have been found to display promising antibacterial activity. This project has the potential to identify compounds that may result in a new antibiotic therapy.
PrtFII, A Streptococcus Pyogenes Fibronectin Binding Protein, And Invasive Diseases.
Funder
National Health and Medical Research Council
Funding Amount
$296,540.00
Summary
Our recent work revealed that, in the Aboriginal population, young age is a risk factor for severe invasive diseases caused by group A streptococcus. For group A streptococcus infection to occur, bacterial attachment is the first step. The bacterium attaches to host cells through interactions involving host fibronectin and the pathogen's fibronectin-binding proteins. We have found that streptococcal strains from severe disease cases are more likely to have the gene for PrtFII, a fibronectin bind ....Our recent work revealed that, in the Aboriginal population, young age is a risk factor for severe invasive diseases caused by group A streptococcus. For group A streptococcus infection to occur, bacterial attachment is the first step. The bacterium attaches to host cells through interactions involving host fibronectin and the pathogen's fibronectin-binding proteins. We have found that streptococcal strains from severe disease cases are more likely to have the gene for PrtFII, a fibronectin binding protein, than those from uncomplicated skin sores. In this application we propose to extend this observation and compare biochemical properties of PrtFII from strains belonging to the above two sets of collections. We hypothesise that PrtFII from invasive strains bind to fibronectin more tightly than the proteins from strains that cause uncomplicated infection. We also will test whether sera from invasive disease cases have lower titre of antibodies to the conserved region of PrtFII than sera from uncomplicated cases. A streptococcal vaccine by necessity has to be a multi-component vaccine to cover a wide spectrum of diseases and epidemiological differences. The study proposed here may provide a basis to argue whether or not to include PrtFII in such a multi-component vaccine.Read moreRead less
Rhinovirus impairs physiological and immunological lung development and causes exacerbation of allergic airways disease. Rhinovirus (RV) infections account for around 90 per cent of asthma exacerbations, yet the mechanisms behind this are unknown. This project will use mouse models to study the effects of early life RV infection and allergic sensitisation on respiratory and immunological development, with the expectation that early life RV infection disrupts anitgen presenting cell function.
Seeking causes of unexplained respiratory illness in children by identifying new respiratory viruses. Many respiratory illnesses including the common cold, ear infections, asthma attacks, the flu and pneumonia have no known cause even after all specimen testing is complete. This project will use 'virus hunting' experience to find and sequence as-yet-undiscovered viruses from such specimens so that they can be studied in more detail.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100071
Funder
Australian Research Council
Funding Amount
$290,000.00
Summary
Chemi–biology computational platform for lead discovery in infectious disease. A challenge in fighting infectious disease is in finding new bioactive compounds. This facility will provide a high performance computational environment designed to accelerate the discovery of quality compounds for use in anti-infective medicine.